BSE filing, NSE: ZIMLAB. Summary written from the filing by ALFA Finder's alert engine.
Zim Laboratories Ltd: key numbers
- Share price
- ₹134.00
- Market cap
- ₹719.0 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 194.5×Sector 46.1×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Board Meeting Date
Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.
Zim Laboratories Regulatory Approval
Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.
- From
- Therapeutic Goods Administration (TGA), Australia
Zim Laboratories Credit Rating
CARE Ratings has reaffirmed the credit ratings of Zim Laboratories Limited for its bank facilities, revising the outlook on long-term facilities to negative.
Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr
Zim Laboratories Merger & Restructuring
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
Zim Laboratories Acquisition Worth ₹1.56 Cr
ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.
- Value
- ₹1.56 Cr
Other other announcement announcements
All →Infronics Systems Other Announcement
Infronics Systems appointed R & A Associates as Secretarial Auditor for FY 2026-27. This is a routine statutory appointment with no financial impact.
- Execution
- FY 2026-27
Onix Solar Energy Other Announcement
Onix Solar Energy's monitoring agency reports its rights issue proceeds are fully utilised. The report covers the quarter ended 30 September 2026.
Steamhouse India Other Announcement
Steamhouse India's Reg 32 statement confirms no deviation in IPO fund utilisation from prospectus objects for the quarter ended September 30, 2026. It also discloses a rectified issue-expense figure reallocating Rs 53.5 million to general corporate purposes.
Pine Labs Other Announcement
Pine Labs Limited filed CARE Ratings' Monitoring Agency Report for the quarter ended September 30, 2026, on its IPO proceeds. The report shows no deviation from objects and no major deviations.
Sihora Industries Other Announcement
Sihora Industries reported IPO proceeds utilisation of Rs.983.87 lakh of Rs.1,056 lakh raised, to September 2026. Shareholders approved the object deviation on 17 August 2026.
Titan Company Other Announcement
Titan's employee stock option trust transferred 19,385 shares worth Rs.8.40 Crore to eligible employees after PSU exercise. The off-market transfer was disclosed under PIT Reg 7(2).
- Value
- ₹8.40 Cr